Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide and Left Ventricular Mass in HFpEF: The SUMMIT Imaging Substudy

A year of tirzepatide in obesity-related HFpEF reduced left ventricular mass by 11 g and paracardiac fat by 45 mL against placebo. The change in heart mass tracked the change in body weight.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Difference from placebo at 52 weeksChange95% CILeft ventricular mass−11 g−19 to −4 gFat around the heart−45 mL−69 to −22 mL

In the SUMMIT imaging substudy, participants who received tirzepatide had a greater decrease in left ventricular mass and fat around the heart than those who received placebo. Participants had obesity and heart failure with preserved ejection fraction (HFpEF). The scans measured how heart structure changed over 52 weeks [1].

What the scans showed

The substudy used cardiac MRI to measure the muscle mass of the left ventricle, the heart’s main pumping chamber, and paracardiac fat, which includes fat in and around the sac that encloses the heart. Of the 175 people scanned at baseline, 106 had usable scans at baseline and week 52: 50 on tirzepatide and 56 on placebo [1].

Compared with placebo, the change with tirzepatide was −11 g for left ventricular mass (95% confidence interval −19 to −4 g) and −45 mL for paracardiac fat (95% confidence interval −69 to −22 mL). The estimates come from participants with two usable scans, about three in five of those scanned at baseline [1].

How the scans relate to heart failure events

Our guide to tirzepatide’s heart evidence covers several trials with different patient groups and outcomes. The main SUMMIT trial specifically enrolled 731 adults with obesity and heart failure with an ejection fraction of at least 50%. Over a median 104 weeks, 9.9% on tirzepatide and 15.3% on placebo experienced cardiovascular death or a worsening heart-failure event (hazard ratio 0.62, 95% confidence interval 0.41–0.95) [2].

Worsening heart failure occurred in 8.0% on tirzepatide and 14.2% on placebo. Cardiovascular death alone was less common and the estimate was imprecise: 2.2% versus 1.4% (hazard ratio 1.58, 95% confidence interval 0.52–4.83) [2]. The imaging authors suggested the smaller heart muscle mass and lower fat volume could have contributed to the clinical result. The substudy did not establish that either imaging change caused the difference in heart failure events [1].

Frequently asked

What changed on cardiac MRI with tirzepatide?
At 52 weeks, the estimated differences from placebo were 11 g less left ventricular mass and 45 mL less paracardiac fat in adults with obesity and HFpEF.
Was the change caused by weight loss?
Left ventricular mass and body weight changes were associated in the tirzepatide group. The substudy could not determine how much of the imaging change weight loss explained.
How many people were included in the imaging analysis?
175 had baseline scans. Of those, 106 had usable scans at both time points, with 50 on tirzepatide and 56 on placebo.
Did the cardiac MRI study measure heart failure events?
The MRI substudy measured heart structure. The main SUMMIT trial separately found that 9.9% of the tirzepatide group and 15.3% of the placebo group experienced worsening heart failure or cardiovascular death.

Sources

  1. [1] Kramer CM, et al. (2025). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Journal of the American College of Cardiology. PMID 39566869
  2. [2] Packer M, Zile MR, Kramer CM, et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity New England Journal of Medicine. PMID 39555826

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence